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We report a molecular typing and epidemiologic analysis of
Pneumocystis carinii pneumonia (PCP) cases diagnosed in our
geographic area from 1990 to 2000. Our analysis suggests that
transmission from patients with active PCP to susceptible per-
sons caused only a few, if any, PCP cases in our setting.
neumocystis carinii pneumonia (PCP) is an important
cause of illness and death in immunocompromised
patients, specifically HIV-infected patients, transplant recipi-
ents, and patients with oncohematologic diseases. In the
absence of a reliable method of in vitro culture of the patho-
gen, many aspects of PCP epidemiology remain to be eluci-
dated (1). Because of the evidence that contact with P. carinii
occurs early in life, clinical infection in adults was thought to
be mostly the result of reactivation of latent organisms. How-
ever, this concept has been challenged by evidence of the
occurrence of de novo infection in HIV-infected persons (2,3).
Possible sources include the environment, asymptomatic carri-
ers, unrecognized infections, and patients with active PCP.
Carriage by some persons with severe immunosuppression (4)
or with chronic pulmonary disease (5) has been described
recently. Direct transmission of P. carinii from patients with
active PCP to susceptible persons is suggested by numerous
reports of clusters of PCP cases, as well as by the demonstra-
tion of transmission of P. carinii in animal models (6). How-
ever, recent molecular typing failed to support this hypothesis
in some studies (7–9). Indeed, different molecular P. carinii
types were found in members of three different couples diag-
nosed with PCP (7), and the types were often different within
clusters of PCP cases (8,9). Using molecular typing and epide-
miologic analysis, we investigated the possibility of transmis-
sion of P. carinii between PCP patients who were seen in our
region (about 500,000 inhabitants) during recent years. With
few exceptions, all PCP patients are diagnosed at or referred to
our hospital, Centre Hospitalier Universitaire Vaudois. 
From October 1990 to August 2000, 1,299 bronchoalveo-
lar lavage specimens were examined at our hospital by using
the Gomori staining method; 230 (18%) were positive for P.
carinii (including eight recurrent episodes), among which 131
(57%) were available for typing (127 patients, four recurrent
episodes). The typing system consisted of amplification by
polymerase chain reaction (PCR) of four variable regions of
the P. carinii genome, followed by the detection of the poly-
morphisms using the single-strand conformation polymor-
phism technique (SSCP). The four genomic regions are: the
internal transcribed spacer number 1 of the nuclear rRNA
genes operon, the intron of the nuclear 26S rRNA gene, the
variable region of the mitochondrial 26S rRNA gene, and the
region surrounding the intron number 6 of the beta-tubulin
gene. These four genomic regions were shown to be stable
over prolonged periods of time by using SSCP (10). The inter-
pretation of SSCP results for typing has been described
(11,12). A P. carinii type is defined by a combination of four
alleles corresponding to the four genomic regions. This system
has been validated (10–12). The SSCP typing system is easier
and faster than DNA sequencing of multiple loci and allows
the analysis of large collections of specimens. Moreover, this
system detects a higher proportion of coinfections than typing
by DNA sequencing of several genetic loci, probably because
it is more sensitive at detecting alleles present in low amounts
(11,13). This higher rate of detection is important for epidemi-
ologic studies. The disadvantage of SSCP is that specimens
containing more than two P. carinii types (about 30% of the
specimens) cannot be typed because of the complexity of the
alleles’ configuration (11).
The ages of the 127 patients ranged from 25 to 82 years
(median 38), and 93 (73%) were men. Seventy-three percent
(93/127) of the patients were HIV infected, and 27% (34) were
immunosuppressed from other conditions. Twenty-three
(18%) of the 131 PCP episodes corresponded to an infection
with a single P. carinii type, 66 (50%) to a coinfection with
two types, and 42 (32%) to a coinfection with more than two
types. The four patients with two PCP episodes were infected
with different types at each episode. Altogether, 35 different
PCR-SSCP types were observed (numbered as in a previous
publication [10]).
To evaluate the proportion of PCP cases that could have
resulted from transmission of P. carinii from a patient with
active PCP to a susceptible person, we analyzed the distribu-
tion over time of the P. carinii types observed in the patients
carrying one or two types (89 episodes, 39% of the cases in the
period). Described clusters of PCPs (14–16) suggest that the
incubation period of P. carinii infection may range from 3 to
12 weeks, which is also in accordance with experiments in ani-
mals (17,18). Accordingly, we hypothesized that the incuba-
tion period of a newly acquired infection would range from 3
weeks to 3 months and that a patient with PCP might be infec-
tious from 1 month before diagnosis until the end of treatment
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(usually 3 weeks after diagnosis). A patient can be both a
receptor of P. carinii and a donor. The Figure represents the
receptor-donor period for each P. carinii type identified in a
patient (a patient with a coinfection has two types). The distri-
bution of the types over time was relatively homogeneous,
suggesting the absence of outbreaks due to a single type. In
only 19 instances did the periods of two or more isolates of a
given type overlap. 
To investigate whether these overlapping periods could
reflect transmission of P. carinii between the members of the
cluster, we calculated, for each type, the multinomial probabil-
ity that the observed clusters occurred by chance alone using
Monte-Carlo simulation experiments (we assumed uniform
distribution over time). For types 1, 10, and 11, the probability
was small (4.6%, 5.6%, and 5.4%, respectively). This proba-
bility is even smaller when we consider only 1990–1995
(before antiretroviral tritherapy was introduced), a period dur-
ing which more cases were observed (1.5%, 2.3%, and 1.5%,
respectively). This probability suggests that some clusters may
indeed be the result of interhuman transmission of P. carinii
(or of infection from a common source). However, 16 of the 19
clusters involved patients infected with different coinfecting
types, implying that interhuman transmission was less likely
(either the donor would have not transmitted both types or the
receptor would have acquired one type elsewhere, or both).
We further investigated the possibility of transmission
between members of each cluster using available epidemio-
logic data limited to the location of patients’ residence and
documented time in the hospital. None of the patients involved
in the 19 clusters lived in the same city sector or the same
town. To investigate the possibility of encounters in the hospi-
tal, timing and location of consultations and hospitalizations
were determined by review of the patients’ medical charts and
the outpatient clinic’s schedule. An encounter was considered
compatible with an interhuman transmission of P. carinii if an
“infectious” and a “susceptible” patient (as defined above)
were present in the same ward or facility of the hospital on the
same day. Analyses of all identified clusters did not reveal any
hospital encounters. Because the period at risk of acquisition
and transmission chosen might have been too restrictive, we
also analyzed four clusters of patients with identical typing
results but with PCP episodes occurring up to 10 months apart.
Again, no encounter in the hospital, as defined above, was
found. 
Because the analyzed specimens represent only 39% (89/
230) of the PCP episodes of the period, the possibility of a
selection bias can be raised. Such bias cannot be firmly
excluded but statistical analysis argues against it, at least for
the period before antiretroviral tritherapy was introduced (a
period covering 51% [87/171] of the specimens available).
Statistical analysis showed that the distribution over time of
the available specimens was not significantly different from
that of the cases that were unavailable (Wilcoxon rank sum
test; p=0.55), suggesting that the results for this period are rep-
resentative of the overall situation. On the other hand, the two
distributions for the period from 1996 to 2000 were different
because the proportion of specimens stored for typing
increased regularly during the period (p=0.07; 75% [44/59] of
the specimens available).
Our study reports on a large number of PCP episodes
observed for >10 years. Although our retrospective analysis
does not allow us to exclude encounters of the clustered cases
outside the hospital, the results strongly suggest that transmis-
sion of P. carinii by a patient with active PCP to a susceptible
person contributed to only a very small number, if any, of the
PCP cases in our geographic area during this period. The
broad diversity of observed types suggests that the patients
acquired P. carinii from multiple unknown sources not
addressed in the present study. Moreover, hospital epidemio-
logic data and molecular typing did not provide evidence of
transmission of P. carinii inside the hospital between members
of clusters infected with the same P. carinii type. Thus, the
main source of P. carinii is unlikely to be represented by
patients with active PCP.
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